Goldman Sachs’s Tandem Diabetes Care TNDM Stock Holding History

Goldman Sachs’s Portfolio TNDM Stock Details TNDM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-27,200	Closed	-$1.15M	–	6266
2024 Q3	$1.15M	Buy	+27,200	New	+$1.15M	﹤0.01%	4539
2022 Q3	–	Sell	-26,500	Closed	-$1.57M	–	6533
2022 Q2	$1.57M	Hold	26,500	–	–	﹤0.01%	4261
2022 Q1	$3.08M	Buy	+26,500	New	+$3.09M	﹤0.01%	3833
2016 Q2	–	Sell	-4,700	Closed	-$409K	–	7255
2016 Q1	$409K	Buy	+4,700	New	+$411K	﹤0.01%	4956
2015 Q4	–	Sell	-5,840	Closed	-$515K	–	7340
2015 Q3	$515K	Buy	+5,840	New	+$680K	﹤0.01%	5112
2015 Q1	–	Sell	-10,000	Closed	-$1.27M	–	7286
2014 Q4	$1.27M	Buy	+10,000	New	+$1.39M	﹤0.01%	4311

Other funds holding TNDM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

GKIM

GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Goldman Sachs's TNDM Position: Q1 2026 in Review

Goldman Sachs increased its Tandem Diabetes Care (TNDM) stake by 32% in Q1 2026, buying an estimated $11.6M and bringing the position to 2,218,922 shares worth $42.5M. The position accounts for ﹤0.01% of the portfolio, ranked #1707.

Goldman Sachs first reported a position in TNDM in Q4 2013 and has held it in 40 quarters since. The position peaked at $140M in Q4 2021. 272 funds tracked by Wall St. Rank hold TNDM as of Q1 2026.

Goldman Sachs held 2,218,922 shares of Tandem Diabetes Care worth $42.5M as of Q1 2026.
Goldman Sachs bought 535,522 Tandem Diabetes Care shares in Q1 2026, an estimated $11.6M.
Tandem Diabetes Care made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #1707 holding.
Goldman Sachs first reported a position in Tandem Diabetes Care in Q4 2013 and has held it in 40 quarters since.
Goldman Sachs's Tandem Diabetes Care position peaked at $140M in Q4 2021.
272 funds tracked by Wall St. Rank held Tandem Diabetes Care as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.